(Q35537489)

8 August 2017

title

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

8 August 2017

0 references

1 reference

11

Ludwig Kappos

1 reference

8 August 2017

10

Gavin Giovannoni

1 reference

8 August 2017

Jens Kuhle

1

1 reference

8 August 2017

Giulio Disanto

2

1 reference

8 August 2017

Johannes Lorscheider

3

1 reference

8 August 2017

Tracy Stites

4

1 reference

8 August 2017

Yu Chen

5

1 reference

8 August 2017

Frank Dahlke

6

1 reference

8 August 2017

Gordon Francis

7

1 reference

8 August 2017

Anupama Shrinivasan

8

1 reference

8 August 2017

Ernst-Wilhelm Radue

9

1 reference

8 August 2017

language of work or name

English

0 references

publication date

25 March 2015

1 reference

8 August 2017

number of pages

5

1 reference

based on heuristic

inferred from page(s)

published in

Neurology

1 reference

8 August 2017

volume

84

1 reference

8 August 2017

issue

16

1 reference

8 August 2017

page(s)

1639-1643

1 reference

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

8 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409586

Increased neurofilament light chain blood levels in neurodegenerative neurological diseases

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409586

Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409586

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409586

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409586

Natural history of multiple sclerosis: a unifying concept

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409586

Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409586

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409586

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409586

A comparative study of CSF neurofilament light and heavy chain protein in MS

26 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25809304

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1212/WNL.0000000000001491

1 reference

8 August 2017

1 reference

8 August 2017

1 reference